A New Financial Hope for Start-ups Focused on Cancer

25/09/2014 - 2 minutes

Aglaia is a new venture capital fund that will invest in about ten to fifteen biotechnology start-ups developing groundbreaking technologies to prevent and cure cancer.

The Dutch venture has announced the launch of Aglaia Oncology Fund II. Investors contribute with $65M (EUR 51M)  for the fund, to reach $80M (EUR 63M) to $100M (EUR 80M). Like its predecessor Aglaia Oncology Fund I, the fund is backed by high-net-worth families. The group of investors has been expanded to include several institutional investors, including the European Investment Fund, which has made a substantial commitment. Aglaia is also one of the funds selected under the Dutch Venture Initiative, an investment fund recently launched by the Netherlands Ministry of Economic Affairs.

Public demand for new oncology products is substantial. Approximately 21.4 million people may be diagnosed with cancer in 2030, with more than 13 million of these cases resulting in a fatal outcome. The fight against cancer has become one of the largest and fastest-growing areas of the pharmaceutical industry.

A fast growing number of high-potential start-ups operating in this field are in an early stage of technological development.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member